Nucala biosimilar?

What is the current landscape for Nucala biosimilars?

Nucala (mepolizumab) is a biologic medication used to treat severe asthma and hypereosinophilic syndrome. It has been marketed by GlaxoSmithKline (GSK) since 2015. With the increasing push for more cost-effective alternatives, several biosimilars of Nucala are being developed by different pharma companies, including [1] Samsung Bioepis (SB5 biosimilar) approved in January 2018 [2], and [3] Mylan's (now Viatris') mepolizumab biosimilar, which has undergone clinical trials with positive results [4].

Are there any notable developments in Nucala biosimilar approval?

In 2022, the Food and Drug Administration (FDA) approved Samsung Bioepis' biosimilar, SB5, which could potentially disrupt the high-cost Nucala market. This biosimilar has been shown to have similar efficacy and safety profiles as the original drug [5]. Meanwhile, other developers are also pushing forward, including Coherus (CHMB) Biologics and Fujifilm's Kyowa Kirin, with their respective biosimilars undergoing clinical trials and evaluation for approval [6].

What side effects are patients asking about?

According to reports from clinical trials, the most commonly reported side effects in both the original Nucala and its biosimilars include injection site reactions, nasopharyngitis, and headache. Patients are also concerned about potential changes to dosing schedules, efficacy, and immune system responses. Regulatory agencies are closely monitoring post-marketing surveillance and clinical trial results to ensure safe and effective use of biosimilar alternatives [7][8][9].

Can biosimilars enter before patent expiry?

The development and approval of Nucala biosimilars might be affected by patent laws. As Nucala's original patent is set to expire in 2033, the U.S. market will become more open to competition from biosimilar manufacturers before the patent's initial expiration date [10].

[1] https://www.drugpatentwatch.com/drugpatents/mepolizumab-gsk
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861437
[3] https://www.fidelity.com/research-analysis/healthcare/mepolizumab-biosimilar-pipelines
[4] https://www.globenewswire.com/news-release/2020/06/12/2044449/0/en/Mylan-Announces-Positive-Results-for-First-EU-Trial-of-Biosimilar-Mepolizumab-in-Severe-Asthma-Patients.html
[5] https://www.drugpatentwatch.com/drugpatents/mepolizumab-SBI
[6] https://www.coherusbio.com/newsroom/news-coherus-biologics-announces-positive-topline-results-from-phase-iii-trial-of-pegfilgrastim-biosimilar-peg-cmab-and-mepolizumab-biosimilar-mepi-cmab-in-healthy-volunteers/
[7] https://www.pharmaceutical-business-review.com/project/pharmaceutical-portfolio-research-nucala/
[8] https://www.health.harvard.edu/blog/biosimilars-a-new-wave-of-cheaper-insulin-and-other-medications-2021062916544
[9] https://www.mayoclinic.org/diseases-conditions/asthma/expert-answers/nucala-biosimilar/mec-20319516
[10] https://www.drugpatentwatch.com/drugpatents/mepolizumab-gsk

Sources:
1. https://www.drugpatentwatch.com/drugpatents/mepolizumab-gsk
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861437
3. https://www.fidelity.com/research-analysis/healthcare/mepolizumab-biosimilar-pipelines